Pfizer get USFDA nod for XELJANZ (tofacitinib) to treat active polyarticular course juvenile idiopathic arthritis Read more
Bispecific antibodies will mature after 2021, $6bn estimated sales in oncology by 2025: GlobalData Read more
IONTAS and FairJourney Biologics find COVID-19 neutralizing antibodies with picomolar potency Read more